[{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dichlorphenamide","moa":"CA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Torrent Pharmaceuticals Limited \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Torrent Pharmaceuticals Limited

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.

Product Name : Keveyis-Generic

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

June 04, 2023

Lead Product(s) : Dichlorphenamide

Therapeutic Area : Genetic Disease

Highest Development Status : Approved FDF

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

blank